Trial · NCT07122635
Effectiveness of Dry Eye Treatment With Diquafosol Sodium 3% After Phaco Surgery
NCT07122635, Completed, Le Xuan Cung
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effectiveness of Dry Eye Treatment With Diquafosol Sodium 3% After Phaco Surgery. Trials, record NCT07122635. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07122635
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effectiveness of Dry Eye Treatment With Diquafosol Sodium 3% After Phaco Surgery
- NCT number
- NCT07122635
- Status
- Completed
- Enrollment
- 60 participants, actual
- Lead sponsor
- Le Xuan Cung
- Conditions
- Dry Eye Disease
- Interventions
- Diquafosol Sodium 3%
- First posted
- 2025-08-14
- Last updated
- 2025-08-14
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in OSDI score | From starting diquafosol (baseline) to 12 weeks | Change in OSDI score after treatment with diquafosol from baseline (1 week after surgery) to 4 weeks, 8 weeks, 12 weeks. At the preoperative and postoperative examinations, patient will be evaluated dry eye symptoms according to the OSDI questionnaire (from 0-100 points) |
| Primary | Change in Tear film breakup time (TBUT) score | From starting diquafosol (baseline) to 12 weeks | Change in tear film breakup time (TBUT) score after treatment with diquafosol from baseline (1 week after surgery) for 4 weeks, 8 weeks, 12 weeks. At the preoperative and postoperative examinations, patient will be evaluated tear film breakup time which is measured after fluorescein staining. At each examination, TBUT score is measured 3 times to calculate the average value. |
| Secondary | Change in Schirmer I test value | From starting diquafosol (baseline) to 12 weeks | Change in Schirmer I test value after treatment with diquafosol from baseline (1 week after surgery) for 4 weeks, 8 weeks, 12 weeks. At the preoperative and postoperative examinations, patient will be evaluated total tear secretion using the Schirmer I test. |
| Secondary | Change in Tear meniscus height | From starting diquafosol (baseline) to 12 weeks | Change in Tear meniscus height after treatment with diquafosol from baseline (1 week after surgery) for 4 weeks, 8 weeks, 12 weeks. At the preoperative and postoperative examinations, tear meniscus height will be measured using TMH mode on Keratograph 5M machine. |
| Secondary | Change in Corneal staining score | From starting diquafosol (baseline) to 12 weeks | Change in corneal staining score after treatment with diquafosol from baseline (1 week after surgery) for 4 weeks, 8 weeks, 12 weeks. At the preoperative and postoperative examinations, patient will be evaluated corneal staining score, which is measured after fluorescein staining and calculated according to NEI grading scale. |
| Secondary | Change in Conjunctival staining score | From starting diquafosol (baseline) to 12 weeks | Change in conjunctival staining score after treatment with diquafosol from baseline (1 week after surgery) for 4 weeks, 8 weeks, 12 weeks. At the preoperative and postoperative examinations, patient will be evaluated conjunctival staining score, which is measured after Lissamine green staining and calculated according to NEI grading scale. |
| Secondary | Change in Tear film breakup pattern | From starting diquafosol (baseline) to 12 weeks | Change in tear film breakup pattern from baseline (1 week after surgery) and after 12 weeks of treatment with diquafosol. Tear film breakup pattern will be assessed after fluorescein staining. |
| Other | Rate of side effects of diquafosol | From starting diquafosol (baseline) to 12 weeks | Rate of side effects of diquafosol will be assessed at each examination. |
| Other | Influence of Risk Factors on Treatment Effectiveness | From starting diquafosol (baseline) to 12 weeks | The influence of risk factors on treatment effectiveness will be evaluated (yes or no, influence or not). A Fisher's Exact Test will determine if there is a statistically significant difference (p\<0.05) between subgroups of a specific risk factor. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07122635
GET https://conductscience.org/api/trials/v1/NCT07122635/registered